ARA-290 (Cibinetide)
A peptide that awakens your body's natural repair system to heal damaged nerves and reduce pain
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
1 – 8 mg
Compound profile
Scientific & efficacy data
Healing & Recovery
Peptide profile
Moderate human trials
ARA-290 (Cibinetide)
1 mg · Once daily
Molecular formula
C51H84N16O21
- Mol. weight
- 1257.31 g/mol
- CAS number
- 1208243-50-8
- PubChem
- 91810664
- Developed · 2008
- Araim Pharmaceuticals Research Team
Araim Pharmaceuticals
Amino acid sequence
{Glp}-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-SerNerve Regeneration
ARA-290 actively regrows small nerve fibers that die from diabetes, neuropathy, or injury. Studies show real improvements in nerve density on corneal imaging.
Pain Management
Reduces neuropathic pain through both nerve repair and anti-inflammatory pathways. Users report decreased shooting pain and burning sensations.
Tissue Protection
Protects pancreatic cells, organs, and tissues from stress damage. Works especially well in diabetes where tissues face constant oxidative harm.
Dosing
How much do I take?
1 – 8 mg · once daily · subcutaneous
1 – 8 mg
Once daily
Covers all 4 documented dose levels · 2 administration routes · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for treating small fiber neuropathy & managing neuropathic pain from diabetes or sarcoidosis
Best for
Treating small fiber neuropathy
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on treating small fiber neuropathy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing neuropathic pain from diabetes or sarcoidosis
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on managing neuropathic pain from diabetes or sarcoidosis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting nerve regeneration after injury
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on supporting nerve regeneration after injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing chronic inflammation
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on reducing chronic inflammation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare ARA-290 (Cibinetide) with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Subcutaneous injection · Intravenous injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
3 common side effects · 3 serious
ARA-290 is a synthetic innate repair receptor agonist that has completed Phase 2 clinical trials for small fiber neuropathy and is under active development.
Animal toxicology studies show a good safety margin with no organ damage or cytotoxicity at doses far exceeding therapeutic levels. Early clinical data from Phase 2 trials demonstrate tolerability with mild injection site reactions and transient headache as primary concerns.
However, immunogenicity remains a potential risk with repeated dosing of synthetic peptides, requiring anti-drug antibody monitoring. Long-term safety data beyond 12 weeks does not yet exist.
Evidence comes from preclinical toxicology studies, Phase 1 dose-escalation and safety data, and Phase 2 efficacy trials in small fiber neuropathy patients. The phase 2 trial enrolled 127 patients with a primary endpoint of safety and tolerability.
No serious adverse events directly attributable to ARA-290 were reported in early studies. Data suggests good safety at doses up to 1 mg subcutaneously twice weekly, but longer-term outcomes and immunogenicity assessments continue.
Common side effects · experienced by some users
Injection Site Reactions
Redness, mild swelling, or bruising at injection site lasting a few hours to a day
Management: Rotate injection sites, apply ice pack after injection, massage gently to improve absorption
Headache
Mild to moderate headache typically in first few hours after injection
Management: Stay hydrated, rest in a quiet space, over-the-counter pain reliever if needed
Dizziness
Brief dizziness or lightheadedness, especially when standing up quickly
Management: Rise slowly from sitting or lying, avoid sudden movements, inform your doctor if persistent
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with ARA-290 (Cibinetide)
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
ARA-290 (Cibinetide) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Alpha Lipoic Acid — Enhances antioxidant protection and reduces inflammation to complement nerve regeneration
- Safe:Benfotiamine — Fat-soluble form of B1 vitamin that supports nerve function alongside ARA-290's regenerative effects
- Safe:Vitamin B12 — Essential for nerve health and myelin formation, works synergistically with nerve repair
With medications
- Caution:Erythropoietin (EPO) — Both activate similar pathways; combining could cause excessive red blood cell production
- Caution:Uncontrolled antihypertensive medications — May cause dangerous blood pressure fluctuations
- Caution:Anticoagulants at high doses — May increase thrombosis risk
With supplements
- Safe:Multivitamins — Generally safe to take alongside ARA-290 (Cibinetide). Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Moderate human trials · first signs week 1-2: initial response (first two weeks)
Evidence level
Moderate human trials
(Phase 1-2)
Regulatory status
Not FDA approved
Onset of effects
Moderate
(1-2 weeks)
How it works
ARA-290 mimics a naturally occurring peptide (erythropoietin fragment) that reduces inflammation and protects nerves from damage.
It's being developed for conditions like diabetes-related nerve pain where inflammation damages nerve tissues.
The deeper mechanism
ARA-290 (cibinetide) is an erythropoietin-derived peptide that activates the heterodimeric receptor (CD131/βcR) without activating erythropoietin-induced erythropoiesis.
It promotes anti-inflammatory and tissue-protective signaling through JAK/STAT pathways, reducing inflammatory cytokine production and improving neuronal survival in diabetic neuropathy.
What to expect
Week 1-2: Initial Response (First two weeks)
What you might notice
- You may notice improved energy, better sleep, or mild improvement in pain
- Injection site reactions are most common now
- Your body's repair systems are just starting to activate
What's normal
- Initial response to ARA-290 (Cibinetide) is beginning at the cellular level
- Different individuals experience ARA-290 (Cibinetide)'s onset at different rates
- Transient systemic effects from initial ARA-290 (Cibinetide) exposure are common
What's next
- Maintain consistent ARA-290 (Cibinetide) administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Week 3-8: Noticeable Changes (Weeks 3-8)
What you might notice
- Pain reduction becomes more apparent
- Inflammation starts decreasing
- Some users report better blood sugar control
- Nerve regeneration is happening but may not be felt yet
What's normal
- ARA-290 (Cibinetide) is now achieving steady-state pharmacokinetics
- Measurable changes aligned with ARA-290 (Cibinetide)'s mechanism may appear
- Initial adjustment effects typically resolve by this point
What's next
- Maintain ARA-290 (Cibinetide) dosing exactly as established
- Track progress toward intended outcomes in detail
- Review lab work or biomarker changes with your healthcare team
Week 9-16: Significant Improvement (Weeks 9-16)
What you might notice
- Neuropathic pain noticeably reduced
- Increased sensation in feet (if neuropathy was present)
- Better energy and mood
- Healing effects becoming measurable
What's normal
- ARA-290 (Cibinetide) has achieved stable, long-term homeostatic integration
- Sustained efficacy of ARA-290 (Cibinetide) remains consistent
- Chronic ARA-290 (Cibinetide) effects remain stable and predictable
What's next
- Maintain your established ARA-290 (Cibinetide) protocol for sustained benefits
- Continue periodic monitoring to confirm ARA-290 (Cibinetide) efficacy
- Review comprehensive ARA-290 (Cibinetide) response with your provider
Month 4+: Full Benefits Realized (4+ months)
What you might notice
- Maximum nerve fiber regrowth visible on corneal imaging
- Sustained pain reduction
- Improved daily function and quality of life
- Benefits continue with ongoing treatment
What's normal
- Full therapeutic effects of ARA-290 (Cibinetide) are well-characterized at this point
- Maintenance of ARA-290 (Cibinetide)'s therapeutic effects is typical
- Tolerance patterns with ARA-290 (Cibinetide) are generally stable over months
What's next
- Comprehensive assessment of ARA-290 (Cibinetide) efficacy should be conducted
- Discuss long-term continuation, cycling, or protocol modifications
- Continue regular monitoring of relevant biomarkers or symptoms
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to ARA-290 (Cibinetide) over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Clinical trials
Tested in people
3 registered studies, none currently enrolling.
By phase
A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.
What kind of research
About 97 people took part in the studies that actually administered ARA-290 (Cibinetide). Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.
Most recent
The Use of ARA290 for the Treatment of Diabetic Macular Oedema
Belfast Health and Social Care Trust
Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
Araim Pharmaceuticals, Inc.
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
Claes-Göran Östenson
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when ARA-290 (Cibinetide) is named as an intervention; studies that only mention it in passing are not.
Questions
Frequently asked
How is ARA-290 different from regular erythropoietin (EPO)?
ARA-290 is an 11-amino acid fragment derived from EPO. While EPO stimulates red blood cell production, ARA-290 keeps only the tissue-protective, anti-inflammatory, and nerve-regenerating effects. It activates different cellular pathways without causing the problematic increase in red blood cells that EPO does.
How long before I see results from ARA-290?
Most people notice initial improvements like better sleep or reduced inflammation within 1-2 weeks. Significant pain reduction typically appears by week 6-8. However, nerve fiber regeneration (visible on corneal scans) takes 8-16 weeks to become really apparent. Patience is key with this one!
Can ARA-290 cure neuropathy permanently?
ARA-290 regenerates nerve fibers and reduces pain, which is remarkable. However, it's best thought of as a treatment that needs to be continued, especially if the underlying cause (like diabetes) isn't completely controlled. Some improvements may be permanent, but ongoing treatment typically provides best results.
Is ARA-290 safe for diabetics?
Yes, and it's actually particularly helpful for diabetics with neuropathy. Clinical trials showed it improves glucose control and reduces neuropathic pain in type 2 diabetics. However, blood pressure and red blood cell counts should be monitored, as with any peptide therapy.
Can I use ARA-290 if I have cancer history?
This is one of the contraindications. Because ARA-290 activates cell growth and repair pathways, it's considered unsafe for people with active cancer or recent cancer history. Always discuss your complete medical history with your doctor before starting.
How do I inject ARA-290?
Subcutaneous injection (under the skin) is preferred. Common sites include the abdomen, thigh, or upper arm. Some clinical trials used intravenous administration, but subcutaneous is easier for self-administration. Your doctor will provide detailed injection training.
What happens if I stop taking ARA-290?
Many benefits persist because nerve fibers that regenerate tend to stay regenerated. However, inflammation may gradually return and pain might increase over time. This is why continued treatment or maintenance dosing is usually recommended for best long-term results.
Further reading
History & related research
History · since 2008
The healing peptide that reduces pain and protects nerves without the side effects of traditional EPO.
ARA-290, also called Cibinetide, is an eleven-amino-acid peptide designed from erythropoietin (EPO). Unlike EPO, which boosts red blood cells and causes serious side effects, ARA-290 triggers the body's natural healing abilities.
Read the full history of ARA-290 (Cibinetide)Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for ARA-290 (Cibinetide), on one page.